Tue Nov 09 2021

In this podcast, Dr. Rijneveld discusses BCR-ABL1-like acute lymphoblastic leukemia (ALL), a specific subgroup of ALL characterized by an expression profile similar to Ph+ ALL, albeit lacking the BCR-ABL1 rearrangement, and by sensitivity to TKIs. She highlights how TKIs were game-changing for the prognostic of these patients, although their cost and associated toxicities (usually low but fatiguing in the long-term), may still be issues in the clinical practice. Interview with: Anita Rijneveld. Host: Shaun McCann